Previous close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 2.50 |
Expiry date | 2024-07-19 |
Day's range | 0.1000 - 0.1000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a clinical supply agreement with BeiGene, Ltd. (NASD
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC resistant patients - double the PFS of patients in similar studies1,2,3Clinical benefit rate of 55% in evaluable patients includes HR+, HER2+ and TNBC disease - much higher than comparable studies1,2,3 PHILADELPHIA and VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics C
Looking at BriaCell Therapeutics Corp.'s ( TSE:BCT ) insider transactions over the last year, we can see that insiders...